Grupo Tecnico Asesor de Vacunacion Covid-19. Sequential prioritization for vaccination against SARS-CoV-2 in the Mexican population. Preliminary recommendations

被引：20

作者：

Alpuche-Aranda, Celia M. ^{[1
]}

Elena Alvarez-Buylla, Maria ^{[2
]}

Andrus, Jon K. ^{[3
,4
]}

Arias-Ortiz, Carlos ^{[5
]}

Barrientos-Gutierrez, Tonatiuh ^{[6
]}

Bautista-Arredondo, Sergio ^{[7
]}

Cravioto-Quintana, Alejandro ^{[8
]}

Freyermuth-Enciso, Graciela ^{[9
]}

Lopez-Macias, Constantino ^{[10
]}

Martinez-Aguilar, Gerardo ^{[11
]}

de Jesus Medina-Arellano, Maria ^{[12
]}

Orozco-Hernandez, Aidee ^{[2
]}

Pavia-Ruz, Noris ^{[13
]}

Reyes-Teran, Gustavo ^{[14
]}

Maria Ropero, Alba ^{[15
]}

Ignacio Santos-Preciado, Jose ^{[16
]}

Jesus Sanchez-Martin, Maria ^{[17
]}

Schiavon-Ermani, Raffaela ^{[18
]}

Sifuentes-Osornio, Jose ^{[19
]}

Veras-Godoy, Miriam ^{[20
]}

机构：

[1] Inst Nacl Salud Publ, Ctr Invest Enfermedades Infecciosas, Cuernavaca, Morelos, Mexico

[2] Consejo Nacl Ciencia & Technol, Mexico City, DF, Mexico

[3] George Washington Univ, Washington, DC 20052 USA

[4] Univ Colorado, Boulder, CO 80309 USA

[5] Univ Nacl Autonoma Mexico, Dept Genet Desarrollo & Fisiol Mol, Inst Biotecnol, Mexico City, DF, Mexico

[6] Inst Nacl Salud Publ, Ctr Invest Salud Poblac, Cuernavaca, Morelos, Mexico

[7] Inst Nacl Salud Publ, Ctr Invest Sistemas Salud, Cuernavaca, Morelos, Mexico

[8] Univ Nacl Autonoma Mexico, Fac Med, Grp Expertos Asesoramiento Estrateg Inmunizac, Org Mundial Salud, Mexico City, DF, Mexico

[9] Ctr Invest & Estudios Super Antropol Social Sures, San Cristobal de las Casa, Mexico

[10] Inst Mexicano Seguro Social, Unidad Invest Med Inmunoquim, Ciudad De Mexico, Mexico

[11] Inst Mexicano Seguro Social, GTAV Covid 19 Mexico, Unidad Invest Biomed, Ciudad De Mexico, Mexico

[12] Univ Nacl Autonoma Mexico, Inst Invest Jurid, Mexico City, DF, Mexico

[13] Univ Nacl Autonoma Mexico, Hosp Infantil Mexico Federico Gomez, Fac Med, Mexico City, DF, Mexico

[14] Comis Coordinadora Inst Nacl Salud & Hosp Alta Es, Ciudad De Mexico, Mexico

[15] Org Panamer Salud, Washington, DC USA

[16] Consejo Salubridad Gen, Mexico City, DF, Mexico

[17] Org Panamer Salud, Mexico City, DF, Mexico

[18] Colegio Bioet, Coyoacan, Mexico

[19] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico

[20] Ctr Nacl Atenc Salud Infancia & Adolescenda, Mexico City, DF, Mexico

来源：

SALUD PUBLICA DE MEXICO | 2021年 / 63卷 / 02期

关键词：

D O I：

10.21149/12399

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

The supply of the first Covid-19 vaccines to be registered for population use worldwide will be limited in the short and medium term and therefore it is necessary to define population groups that will receive the vaccine initially and subsequently.To this end, Mexico's Covid-19VaccineTechnical Advisory Group has reviewed the documents generated by the WHO and various countries on prioritizing population groups to be vaccinated, including the ethical principles and values in the allocation of these vaccines. The preliminary results of vaccination analysis in relation to the risk of dying from Covid-19 in Mexico identified the greatest benefit of vaccination in prioritizing initially health workers and people aged 60 years or older with or without comorbidities descending every decade of life, in addition to people aged 50 to 59 years with comorbidities. Subsequently, to continue the vaccination in the remaining population. In the presence of a public health crisis, the Covid-19 vaccination strategy would be different from the usual mechanisms of the Universal Vaccination Program. The communication of the Covid-19 vaccination strategy must carry a message to reach and understanding of all, which is transparent about the prioritization criteria adopted, and respectful of the essential principles of equity, universality and the common good.

引用

页码：286 / 307

页数：22

共 26 条

[1]

[Anonymous], WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines

[2]

[Anonymous], 2020, INTERIM FRAMEWORK CO

[3]

[Anonymous], 2006, The world health report: 2006: Working together for health

[4]

[Anonymous], CUALES SON TRABAJOS

[5]

[Anonymous], 2020, Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID19 Vaccine Development

[6]

[Anonymous], Independent report: JCVI statement on COVID-19 vaccination of children aged 12 to 15 years

[7]

[Anonymous], Modernas COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study |

[8]

[Anonymous], IMPACTO EC SOCIAL SA

[9]

[Anonymous], 2020, WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination

[10]

Bubar KM, 2020, medRxiv, DOI [10.1101/2020.09.08.20190629, 10.1101/2020.09.08.20190629v1, DOI 10.1101/2020.09.08.20190629, 10.1101/2020.09.08.20190629]

← 1 2 3 →